Inozyme Q4 2021 Earnings Report
Key Takeaways
Inozyme Pharma reported its full year 2021 financial results, highlighting the progress of its INZ-701 program and the initiation of its first clinical trial for patients with ENPP1 Deficiency. The company's cash, cash equivalents, and investments were $111.8 million as of December 31, 2021, which is expected to fund operations into the first quarter of 2023.
Patient dosing is underway in the Phase 1/2 trial of INZ-701 in patients with ENPP1 Deficiency, with preliminary biomarker and safety data expected in the first half of 2022.
Patient screening is underway for the Phase 1/2 trial of INZ-701 in patients with ABCC6 Deficiency, with the first patient expected to be enrolled in the second quarter of 2022.
The first patient was enrolled in a longitudinal retrospective natural history study in ENPP1 Deficiency and ABCC6 Deficiency.
Sanjay S. Subramanian was appointed as chief financial officer, and Soojin Kim was appointed as senior vice president and chief technical operations officer.